Rod Saponjic


Dr.Saponjic has more than 25 years of drug development experience in the areas of global operations, project management, clinical operations, clinical systems and CRO Management. Prior to Respivant, he was Vice President Global Development Operations at Greenwich Biosciences, responsible for development governance structures, clinical operations, portfolio pipeline process, and supporting the NDA submission and FDA approval for Epidiolex®. Prior to Greenwich, Dr.Saponjic was Vice President, Clinical Operations at Patara Pharma where he was responsible for execution of multiple international Phase 2 studies in the areas of chronic cough, idiopathic pulmonary fibrosis, indolent systemic mastocytosis, and uremic pruritus. Prior to Patara Pharma, he was Vice President of Global Project Management and/or Clinical Operations at Synteract and PRA Health Sciences. Previously, he held senior management positions at biotech, CRO, and Genomics companies including: AirPharma, Alkensa Pharmaceuticals,, Clingenix, and Quintiles. He earned a BA in Psychology at Texas Tech University, MS and PhD in Neuroscience at Texas Christian University, and a Master’s of Business Administration from Baker University.